Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)

NCT04688281 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2021-09-29

No results posted yet for this study

Summary

This study was designed to evaluate the efficacy and safety of Medicurtain®, an antiadhesion barrier in patients who underwent In Situ Decompression for single level and unilateral herniated lumbar intervertebral disc. Subjects were randomly assigned either into Medicurtain® treatment group or control group. Adhesion formations between the two groups at 12 weeks after surgery were compared by using MRI-applied scar score, ODI (Oswestry Disability Index) and VAS.

Conditions

  • Intervertebral Disc Disorder
  • Thoracic Intervertebral Disc Disorders
  • Thoracolumbar Intervertebral Disc Disorders
  • Lumbosacral Intervertebral Disc Disorders
  • Tissue Adhesion, Surgery-Induced

Interventions

DEVICE

Medicurtain®

Medicurtain® 5ml prefilled syringe

DEVICE

GUARDIX-SG®

GUARDIX-SG® 5ml prefilled syringe

Sponsors & Collaborators

  • Shin Poong Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Chong-Suh Lee, MD, PhD · Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea

  • Eun-Sang Kim, MD, PhD · Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea

  • Ki-Tack Kim, MD, PhD · Kyung Hee University Hospital, Gangdong-gu, Sangil-dong 149, Seoul, South Korea

  • Joomyung Kim, MD, PhD · Samsung Medical Center, Gangnam-gu, Ilwon-dong 50, Seoul, South Korea

  • Yong Cheol Yoon, MD, PhD · Hallym University Medical Center, Pyeongchon-dong 896, Anyang, Gyeonggi-do, South Korea

  • Bong-Soon Chang, MD, PhD · Seoul National University Hospital , Jongro-gu, Yeongeon-dong, Seoul, South Korea

  • Byung-Joon Shin, MD, PhD · Soonchunhyang University Hospital , Yongsan-gu, Daesagwan-ro 59, Seoul, South Korea

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-11
Primary Completion
2013-03-25
Completion
2013-03-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04688281 on ClinicalTrials.gov